RARE
Ultragenyx
16.10$
-4.1%
vs. previous close
Closing price · As of: Oct 30, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Ultragenyx (RARE) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 10/20/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 10/19/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Other Events | View report ↗ |
| 10/14/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Entry into a Material Definitive Agreement | View report ↗ |
| 10/07/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Entry into a Material Definitive Agreement | View report ↗ |
| 09/17/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Other Events | View report ↗ |
| 09/15/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/02/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Other Events | View report ↗ |
| 08/19/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Other Events | View report ↗ |
| 08/14/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 08/13/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 08/11/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Other Events | View report ↗ |
| 08/07/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 08/04/2026 | Current report (8-K) | Ultragenyx Pharmaceutical Inc. (RARE): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
| 08/03/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 07/31/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.